Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianji Ning Granule is a Traditional Chinese Medicine (TCM) herbal formulation developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of myasthenia gravis (MG). It is specifically indicated for patients diagnosed with the 'spleen-kidney deficiency' type of MG according to TCM diagnostic criteria. The granule is composed of multiple herbal ingredients intended to tonify the spleen and kidney, thereby addressing the underlying pathology of muscle weakness and fatigue. Clinical research has focused on its efficacy in improving clinical absolute scores and its potential role in modulating serum microRNA (miRNA) expression profiles, such as miR-150 and miR-146, which are associated with the autoimmune response in MG patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jianji ning granule.